We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GV1001

News List

GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal prnasia
March 30, 2021
GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal 'Alzheimer's Research & Therapy'.
GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial prnasia
November 24, 2020
GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of ...
GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019 prnasia
December 16, 2019
Suggests potential as a new drug for treating Alzheimer's disease